Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection

Journal of Gene Medicine

Volumn 13, Issue 1, 2011, Pages 60-72

  Li, Yi ^a   Hu, Yanxin ^a   Jin, Yi ^a   Zhang, Guozhong ^a   Wong, Jonathan ^b   Sun, Lun Quan ^c,d   Wang, Ming ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Antiviral activity; H5N1 influenza virus; Immune response; LE PolyICLC

Indexed keywords

DOUBLE STRANDED RNA; INFLUENZA VACCINE; LIPOSOME; POLYINOSINIC POLYCYTIDYLIC ACID;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNITY; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VACCINATION; LUNG FIBROSIS; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CARBOXYMETHYLCELLULOSE SODIUM; CYTOKINES; DOGS; FEMALE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LIPOSOMES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; POLY I-C; POLYLYSINE; RNA, DOUBLE-STRANDED; RNA, VIRAL; T-LYMPHOCYTES; VACCINES, INACTIVATED; VIRUS REPLICATION;

MUS; ORTHOMYXOVIRIDAE;

EID: 78751682538     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1536     Document Type: Article

References (38)

1. Palese P. Influenza: Ole and new threats. Nature Med 2004; 10: S82-S87.
2. McKimm-Breschkin JL, Selleck PW, Usman TB, et al. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007; 13: 1354-1357.
3. Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193: 1626-1629.
4. De Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-2672.
5. Wong JP, Yang H, Nagata L, et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 1999; 17: 1788-1795.
6. Kende M. Prophylactic and therapeutic efficacy of poly (I, C)-LC against Rift Valley fever virus infection in mice. J Biol Response Mod 1985; 4: 503-511.
7. Levy HB, Lvovsky E, Riley F, et al. Immune modulating effects of poly ICLC. Ann NY Acad Sci 1980; 350: 33-41.
8. Levy HB, Baer G, Baron S, et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in monkeys. J Infect Dis 1975; 132: 434-439.
9. Wong JP, Christopher ME, Salazar AM, et al. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 2007; 25: 3175-3178.
10. Hoffmann, Stech J, Guan Y, et al. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001; 146: 2275-2289.
11. Jin H, Xiao C, Chen Z, et al. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem Biophys Res Commun 2005; 328: 979-986.
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
13. Piriou L, Chilmonczyk S, Genetet N, et al. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000; 41: 289-297.
14. Steel J, Burmakina SV, Thomas C, et al. A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine 2008; 26: 522-531.
15. Ichinohe T, Watanabe I, Ito S, et al. Synthetic double-stranded RNA poly (I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005; 79: 2910-2919.
16. Yasutomi M, Ohshima Y, Omata N, et al. Erythromycin differentially inhibits lipopolysaccharide- or poly (I:C)-induced but not peptidoglycan-induced activation of human monocyte-derived dendritic cells. J Immunol 2005; 175: 8069-8076.
17. Meier WA, Husmann RJ, Schnitzlein WM, et al. Cytokines and synthetic double-stranded RNA augment the T helper 1 immune response of swine to porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 2004; 102: 299-314.
18. Levine AS, Levy HB. Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep 1978; 62: 1907-1912.
19. Wong JPH. Liposome-encapsulated PolyICLC. United States Patent 6468558.
20. Wong JP, Wong JP, Christopher ME, et al. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr Pharm Des 2009; 15: 1269-1274.
21. Garcia-Briones MM, Blanco E, Chiva C, et al. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D. Virology 2004; 322: 264-275.
22. Leticia C-B, Mildred F-C, Graham JB, et al. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J Gen Virol 2001; 82: 1713-1724.
23. Takatsuka N, Hasegawa A, Takamori A, et al. Induction of IL-10- and IFN-producing T-cell responses by autoreactive T-cells expressing human T-cell leukemia virus type I Tax. Int Immunol 2009; 21: 1089-1100.
24. Neff-LaFord H, Teske S, Bushnell TP, et al. Aryl hydrocarbon receptor activation during influenza virus infection unveils a novel pathway of IFN-γ production by phagocytic cells. J Immunol 2007; 179: 247-255.
25. Turner SJ, Olivas E, Gutierrez A, et al. Disregulated influenza A virus-specific CD8+ T cell homeostasis in the absence of IFN-signaling. J Immunol 2007; 178: 7616-7622.
26. Xiao C, Jin H, Hu Y. Effect of the co-stimulatory molecules, 4-1BBL, OX40 l, as adjuvants on the foot-and-mouth disease (FMD) DNA vaccination. Antiviral Res 2007; 76: 11-20.
27. Yin J, Jin H, Kang Y, et al. Efficacy of a modified levamisole adjuvant on the inactivated new castle virus vaccine. Viral Immunol 2006; 19: 525-535.
28. Abdullah Z, Saric T, Kashkar H, et al. Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. J Immunol 2007; 178: 3390-3399.
29. Akahata W, Ido E, Akiyama H, et al. DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles. J Gen Virol 2003; 84: 2237-2244.
30. Aoki F, Kurabayashi M, Hasegawa Y, et al. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am J Respir Crit Care Med 2005; 172: 713-720.
31. Swaisgood CM, French EL, Noga C, et al. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000; 157: 177-187.
32. Kevin MV, Luckhardt TR, Wilke CA, et al. Latent herpesvirus infection augments experimental pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181: 465-477.
33. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007; 117: 530-538.
34. Tracy RM, Bethany BM, Jason BW, et al. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 2008; 177: 771-780.
35. Barry R, Tracey B, Gregory AZ, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 2009; 83: 7062-7074.
36. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c-type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001; 166: 2291-2295.
37. Molina-Molina M, Badia JR, Marin-Arguedas A, et al. Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit. A study of 20 cases. Med Clin (Barc) 2003; 121: 63-67.
38. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001; 120: 209-212.